CGEM | Ticker Profile - Titan Protect

CGEM

Cullinan Therapeutics, Inc.

Healthcare · Biotechnology · NMS

$13.51

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$954M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-6.10

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-48.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$30.00

+122% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 11 analysts covering this stock

About Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

https://cullinantherapeutics.com

Country: United States Employees: 109 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.044

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0039

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.236

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-17.8%

Historical annualised return based on price data

Max Drawdown

-75.5%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-0.09

Very low correlation to market moves

52W High

$16.74

19% below the year high

52W Low

$5.68

138% above the year low

Avg Volume

862,203

Average daily shares traded — higher means easier to buy and sell

Short Ratio

10.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

20.0%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-3.37

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.65

Moderate leverage — manageable

Current Ratio

10.28

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

10.09

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-102,821,128

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-221,039,008

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$38.00

Target Median

$30.00

Target Low

$23.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go